Welcome to our dedicated page for ELEVATION SERIES TRUST news (Ticker: CVGD), a resource for investors and traders seeking the latest updates and insights on ELEVATION SERIES TRUST stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ELEVATION SERIES TRUST's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ELEVATION SERIES TRUST's position in the market.
CresAlta (NYSE Arca: CVGD, CVSM) launched two actively managed ETFs: the CresAlta Global Dividend ETF (CVGD) and the CresAlta Small and Mid-Cap ETF (CVSM). Both draw on strategies refined over 20 years within AMG National Trust’s AMG Capital Management division.
The ETFs use a Section 351 in-kind conversion to accept tax-deferred equity contributions and complement six existing SMA strategies. CVGD targets global dividend-paying stocks for capital appreciation and income, while CVSM focuses on value-oriented SMID-cap equities with improving fundamentals and dividend growth characteristics.